Vesselon

Vesselon has developed a proprietary drug delivery platform that combines an FDA-approved lipid (Imagent®) with ultrasound activation to create 'TriForm' co-formulations of existing drugs. This platform is designed to extend drug lifecycles, improve efficacy, and open new indications through a low-friction regulatory path, as it uses already-approved components and requires no change to the original drug's manufacturing. The company is initially targeting oncology, with programs aimed at enhancing blockbuster drugs like Keytruda, and claims its technology can generate multiple billion-dollar co-formulations before 2030. Vesselon operates as a private, pre-revenue platform company partnering with pharmaceutical firms.

Proprietary drug co-formulation platform using FDA-approved Imagent® lipid microspheres/liposomes and ultrasound activation. Creates 'TriForm' conjugates with existing drugs via a 5-minute, in-clinic sonication process without altering the drug molecule, aiming to enhance biodistribution and efficacy.

Vesselon competes in the broad drug delivery and formulation enhancement space, which includes companies developing nanoparticles, liposomes, and conjugation technologies. Its key differentiation is the use of FDA-approved components, a physical (non-chemical) conjugation process, and ultrasound-triggered activation aimed at creating new patentable entities with a streamlined regulatory path.